Skip to main content
Article thumbnail
Location of Repository

The Virtual International Stroke Trials Archive

By Ali Myzoon, Philip M.W. Bath, John Curram, Stephen M. Davis, Hans-Christoph Diener, Geoffrey A. Donnan, Marc Fisher, Barbara A. Gregson, James Grotta, Werner Hacke, Michael G. Hennerici, Marc Hommel, Markku Kaste, John R. Marler, Ralph L. Sacco, Philip Teal, Nils-Gunnar Wahlgren, Steven Warach, Christopher J. Weir and Kennedy R. Lees


Background and Purpose - Stroke has global importance and it causes an increasing amount of human suffering and\ud economic burden, but its management is far from optimal. The unsuccessful outcome of several research programs\ud highlights the need for reliable data on which to plan future clinical trials. The Virtual International Stroke Trials Archive aims to aid the planning of clinical trials by collating and providing access to a rich resource of patient data to perform exploratory analyses.\ud Methods - Data were contributed by the principal investigators of numerous trials from the past 16 years. These data have been centrally collated and are available for anonymized analysis and hypothesis testing.\ud Results - ”Currently, the Virtual International Stroke Trials Archive contains 21 trials. There are data on 15 000 patients with both ischemic and hemorrhagic stroke. Ages range between 18 and 103 years, with a mean age of 6912 years. Outcome measures include the Barthel Index, Scandinavian Stroke Scale, National Institutes of Health Stroke Scale, Orgogozo Scale, and modified Rankin Scale. Medical history and onset-to-treatment time are readily available, and computed tomography lesion data are available for selected trials.\ud Conclusions - This resource has the potential to influence clinical trial design and implementation through data analyses that inform planning. (Stroke. 2007;38:1905-1910.

Publisher: American Heart Association
Year: 2007
OAI identifier:
Provided by: Nottingham ePrints

Suggested articles


  1. and the German Stroke Registers Study Group. Frequency of thrombolytic therapy in patients with acute ischemic stoke and the risk of in-hospital mortality.
  2. (1992). Assessment of costs relating to hospitalisation of stroke patients in Austria for
  3. (2004). Association. What is stroke? Available at http:// Last accessed
  4. for the ASSIST Investigators. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist.
  5. for the Citicoline Stroke Study Group. A randomized efficacy trial of citicoline in patients with acute ischemic stroke.
  6. (2007). for the ESTAT investigators. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomized controlled trial. doi
  7. for the GAIN Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.
  8. for the GAIN International Steering Committee and Investigators. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial.
  9. for the German Stroke Databank Collaborators. Complications following acute ischaemic stroke.
  10. (1994). for the INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis.
  11. (1995). for the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke.
  12. for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage.
  13. for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke.
  14. for the STICH Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial.
  15. Funding evidence: The National Institute of Neurological Disorders and Stroke clinical trials program.
  16. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.
  17. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolyse in Acute Cerebral Thromboembolism.
  18. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): randomised controlled trial.
  19. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study
  20. (2006). Last accessed
  21. NXY-059 for acute ischemic stroke.
  22. (1981). on behalf of the Auckland Regional Community Stroke (ARCOS) Study Group. Trends in ethnic disparities in stroke incidence in Auckland,
  23. on behalf of the LUB-INT-13 Investigators. Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo.
  24. (1909). on behalf of the VISTA investigators. Predictors of early cardiac morbidity and mortality after ischemic stroke.
  25. Outcomes of ancrod in acute ischaemic stroke.
  26. Pooling of animal experimental data reveals influence of study design and publication bias.
  27. (2000). Risk factors and stroke prevention. Cerebrovasc Dis.
  28. Strengthening acute stroke trials through optimal use of disability end points.
  29. Streptokinase for acute ischemic stroke with relationship to time of administration.
  30. Turpie AGG, for the TAIST Investigators. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
  31. (2006). Last accessed

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.